ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will participate in the following Septemb…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


